


PREVENAR 20[®]

20-valent pneumococcal conjugate vaccine

Read in conjunction with [Disclaimer](#)

Formulary: Unrestricted	
Presentation	Prefilled syringe: 0.5 mL
Classification	20vPVC (20-valent pneumococcal conjugate vaccine)
Indication	<p>Used as part of the Western Australian Immunisation Schedule for infants at:</p> <ul style="list-style-type: none"> • 6 weeks of age*, and; • 4 months of age. <p>Additional dose at 6 months of age is recommended for:</p> <ul style="list-style-type: none"> • Preterm infants born less than 28 weeks gestation; • Aboriginal and Torres Strait Islander infants; • Patients with Medical Risk Conditions – refer to Australian Immunisation Handbook. <p>*6-week vaccinations can be delayed to 8 weeks of age if medically unwell.</p> <p>NOTE: Parent/Guardian consent is to be obtained prior to administration of all vaccinations.</p>
Precautions	Do not give during febrile illness or acute infection.
Monitoring	<p>As per the Immunisation Guideline:</p> <ul style="list-style-type: none"> • Infants receiving immunisations are to have a full set of observations taken prior to immunisation. • Continuous cardiac monitoring for 48 hours following immunisation.
Incompatibility	The vaccine should not be combined with any fluids or other vaccinations prior to administration.
Interactions	Prevenar [®] can be co-administered with other scheduled vaccines. Ensure a different injection site is used.
Side Effects	Very common: Decreased appetite, irritability, drowsiness/increased sleep, fever (pyrexia), vaccination-site erythema, pain, tenderness and/or swelling.
	Common: Diarrhoea, vomiting, rash, fever greater than 38.9°C.
	Uncommon: Seizures (including febrile seizures), urticaria or urticaria-like rash.
	Frequency unknown: Hypersensitivity/allergic reactions, crying, Hypotonic-hyporesponsive episode, restless sleep.
Storage	Refrigerate at 2 to 8°C, do not freeze.

INTRAMUSCULAR	Presentation	Prefilled syringe	
	Dosage	Intramuscular: 0.5 mL	
	Preparation	Ready to use prefilled syringe.	
	Administration	Intramuscular injection ONLY. <ul style="list-style-type: none"> Vigorously shake the pre-filled syringe to obtain a homogenous, white suspension. Visually inspect the vaccine for large particulate matter and discoloration prior to administration. Inject the entire contents of the pre-filled syringe by intramuscular injection as per the Medication Administration Guideline. 	
	Comment	<ul style="list-style-type: none"> Do not use the vaccine if it cannot be re-suspended after shaking. Do not use the vaccine if large particulate matter or discolouration is found after shaking. 	

Related Policies, Procedures, and Guidelines

Clinical Practice Guidelines:

[CAHS Neonatology – Immunisations](#)

Pharmaceutical and Medicines Management Guidelines:

[CAHS Neonatology – Medication Administration Guideline](#)

[WNHS Cold Chain Management for Medications and Vaccines](#)

[CAHS Medication Refrigerators and Freezers](#)



References

AusDI. PREVENAR 20. In: AusDI By Medical Director [Internet]. Australia: AusDI by Medical Director; 2024 [cited 2025 Aug 14]. Available from: <https://www.ausdi.com/>

Australian Government Department of Health and Aged Care. Vaccination for preterm infants [Internet]. Canberra: Australian Government; [updated 2023 Jul 4; cited 2025 Aug 14]. Available from: <https://immunisationhandbook.health.gov.au/contents/vaccination-for-special-risk-groups/vaccination-for-preterm-infants>

Australian Government Department of Health and Aged Care. Prevenar 20 [Internet]. Canberra: Australian Government; [updated 2023 Jul 4; cited 2025 Aug 14]. Available from: <https://immunisationhandbook.health.gov.au/vaccines/prevenar-20>

Document history

Keywords	Pneumococcal, prevenar, vaccine, immunisations				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate				
Version Info:	V5.0 – changed to Prevenar 20 (previously Prevenar 13)				
Date First Issued:	01/10/2001	Last Reviewed:	14/08/2025	Review Date:	14/08/2030
Endorsed by:	Neonatal Directorate Management Group			Date:	26/06/2025
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance		<input checked="" type="checkbox"/>  Std 4: Medication Safety		
<p>Printed or personally saved electronic copies of this document are considered uncontrolled.</p> <p>Access the current version from WNHS HealthPoint.</p>					

This document can be made available in alternative formats on request for a person with a disability.